Search by therapeutic area for drugs approved by the Food and Drug Administration (FDA) for sale in the
United States. Click on an area below to view the complete list of drugs in that category or
review descriptions for our therapeutic
area list to assist you in your search.
FDA Approved Drugs for Musculoskeletal
Drugs Approved in 2013
Actemra ((ocilizumab); Genentech;
For the treatment of Polyarticular Juvenile Idiopathic Arthritis, Approved May 2013
Ilaris (canakinumab); Novartis;
For the treatment of Systemic Juvenile Idiopathic Arthritis, Approved May 2013
Tecfidera (dimethyl fumarate); Biogen Idec;
For the treatment of relapsing multiple sclerosis, Approved March 2013
Drugs Approved in 2012
Aubagio (teriflunomide); Sanofi Aventis;
For the treatment of multiple sclerosis, Approved September 2012
Elelyso (taliglucerase alfa); Pfizer;
For the treatment of Gaucher disease, Approved May 2012
Lyrica (pregabalin); Pfizer;
For the treatment of neuropathic pain associated with spinal cord injury, Approved June 2012
Myrbetriq (mirabegron); Astellas
Pharma US, Inc.;
For the treatment of overactive bladder, Approved June 2012
Neupro (Rotigotine Transdermal System); UCB;
For the treatment of Restless Legs Syndrome, Approved April 2012
Rayos (prednisone) delayed-release tablets; Horizon Pharma;
For the treatment of certain inflammatory diseases, including arthritis, COPD, asthma and psoriatic conditions, Approved July of 2012
Stendra (avanafil); Vivus;
For the treatment of erectile dysfunction, Approved April 2012
Votrient (pazopanib); GlaxoSmithKline;
For the treatment of soft tissue sarcoma, Approved April 2012
Xeljanz (tofacitinib); Pfizer;
For the treatment of moderately to severely active rheumatoid arthritis, Approved November 2012
Drugs Approved in 2011
Actemra (tocilizumab); Genentech;
For the treatment of systemic juvenile idiopathic arthritis, Approved April 2011
Duexis (ibuprofen and famotidine); Horizon Pharma;
For the relief of rheumatoid arthritis and osteoarthritis and prevention of gastric ulcers, Approved April 2011
Drugs Approved in 2010
Actemra (tocilizumab); Genentech;
For the treatment of rheumatoid arthritis, Approved January 2010
Ampyra (dalfampridine); Acorda;
For the improvement of walking in patients with multiple sclerosis, Approved January 2010
Botox (onabotulinumtoxinA); Allergan;
For the treatment of upper limb spasticity, Approved March 2010
Gilenya (fingolimod); Novartis;
For the treatment of relapsing multiple sclerosis, Approved September 2010
Krystexxa (pegloticase); Savient Pharma;
For the treatment of chronic gout (hyperuricemia), Approved September 2010
Prolia (denosumab); Amgen;
For the treatment of postmenopausal women with osteoporosis at high risk for fracture, Approved June 2010
Vimovo (naproxen + esomeprazole); AstraZeneca;
For the treatment of arthritis in patients at risk for NSAID-associated ulcers, Approved April 2010
Xeomin (incobotulinumtoxinA); Merz Pharmaceutical;
For the treatment of cervical dystonia and blepharospasm, Approved July 2010
Xgeva (denosumab); Amgen;
For the prevention of skeletal-related events in patients with bone metastases from solid tumors, Approved November 2010
Xiaflex (collagenase clostridium histolyticum); Auxilium Pharmaceuticals;
For the treatment of Dupuytren’s contracture, Approved February 2010
Drugs Approved in 2009
Cimzia (certolizumab pegol); UCB;
For the treatment of rheumatoid arthritis, Approved May of 2009
Colcrys (colchicine); Mutual Pharmaceuticals;
For gout flares and familial Mediterranean fever, Approved October 2009
Extavia (Interferon beta-l b); Novartis;
For the treatment of relapsing multiple sclerosis, Approved August of 2009
Pennsaid (diclofenac sodium topical solution); Nuvo Research;
For the treatment of osteoarthritis of the knee, Approved November 2009
Sabril (vigabatrin); Lundbeck;
For the treatment of infantile spasms and complex partial seizures, Approved August 2009
Savella (milnacipran hydrochloride); Forest Laboratories;
For the treatment of fibromyalgia, Approved January 2009
Simponi (golimumab); Centocor Ortho Biotech;
For the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, Approved April 2009
Drugs Approved in 2008
Orencia (abatacept); Bristol-Myers Squibb;
For the treatment of Juvenile Idiopathic Arthritis, Approved April 2008
Xenazine (tetrabenazine); Prestwick Pharma;
For the treatment of chorea due to Huntington's disease, Approved August 2008
Drugs Approved in 2007
Amrix (cyclobenzaprine hydrochloride extended release); Cephalon;
For the treatment of muscle spasm associated with acute, painful musculoskeletal conditions, Approved February 2007
Evista (raloxifene hydrochloride); Eli Lilly;
For the treatment/prevention of osteoporosis and reduction of breast cancer risk in postmenopausal women, Approved September 2007
Reclast (zoledronic acid); Novartis;
For the treatment of Paget's disease, Approved April 2007
Reclast (zoledronic acid); Novartis;
For the treatment of postmenopausal osteoporosis, Approved August 2007
Somatuline Depot (lanreotide acetate); Beaufour Ipsen;
For the treatment of acromegaly, Approved August 2007
Drugs Approved in 2005
Boniva (ibandronate); Roche / GlaxoSmithKline;
For the treatment and prevention of osteoporosis, Approved May, 2003 -- UPDATED: NEW FORMULATION APPROVED MARCH, 2005
Naglazyme (galsulfase); BioMarin Pharmaceuticals;
For the treatment of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome), Approved May 2005
Drugs Approved in 2004
Vioxx (rofecoxib); Merck;
For the treatment of rheumatoid arthritis, Approved April 2002 -- UPDATED: WITHDRAWN OCTOBER 2004
Drugs Approved in 2003
Aldurazyme (laronidase); Genzyme;
For the treatment of Mucopolysaccharidosis I (MPS I) in subjects aged 5 to 65, Approved May 2003
Premarin (conjugated estrogens); Wyeth;
For the prevention of postmenopausal osteoporosis and treatment of vasomotor menopause symptoms, Approved July of 2003
Somavert (pegvisomant); Pharmacia & Upjohn;
Injectable formulation for the treatment of acromegaly, Approved March 2003
Velcade (bortezomib); Millennium Pharmaceuticals;
Injectable agent for the treatment of multiple myeloma patients who have received at least two prior therapies., Approved May 2003
Drugs Approved in 2002
Alora; Watson Pharmaceuticals;
Transdermal patch for the prevention of postmenopausal osteoporosis and treatment of vasomotor menopausal symptoms, Approved April 2002
Avinza (morphine sulfate); Elan Pharmaceuticals;
Extended release capsule for the relief of pain requiring continuous, around-the-clock therapy, Approved March 2002
Forteo (teriparatide); Eli Lilly;
For the treatment of Osteoporosis in postmenopausal women and men who are at high risk for a fracture., December 2002
Remicade (infliximab); Centocor Ortho Biotech;
Intravenous infusion for the treatment of rheumatoid arthritis, Approved February 2002
Testim; Auxilium Pharmaceuticals;
External cream for the treatment of male hormone deficiency., Approved October 2002
Vivelle-Dot (estradiol transdermal system); Novartis;
For the prevention of post-menopausal osteoporosis, Approved May 2002
Drugs Approved in 2001
Genotropin (somatropin) injection; Pharmacia & Upjohn;
For the treatment of growth failure in children who were born small for gestational age (SGA), Approved July 2001
Kineret; Amgen;
Injectable therapy for the treatment of rheumatoid arthritis, Approved November 2001
Supartz; Smith & Nephew Orthopaedics;
Joint fluid therapy for treatment of osteoarthritis in the knee, Approved January 2001
Drugs Approved in 2000
Activella (Estradiol/Norethindrone Acetate) Tablets; Novo Nordisk;
Combination hormone replacement therapy for the prevention of osteoporosis and other symptoms associated w/postmenopause, Approved April 2000
Mobic (meloxicam) Tablets; Boehringer Ingelheim;
For relief of the signs and symptoms of osteoarthritis, Approved April 2000
Myobloc; Elan Pharmaceuticals;
Injectable solution for the treatment of abnormal head position and neck pain associated with cervical dystonia, Approved December 2000
Drugs Approved in 1999
Evista (raloxifene hydrochloride); Eli Lilly;
Osteoporosis treatment, Approved September 1999
Femhrt Tablets; Parke-Davis;
Norethindrone acetate (1mg) and ethinyl estradiol tablets (5mcg), October 15, 1999
Drugs Approved in 1998
Actonel; Procter & Gamble, Hoechst Marion Roussel;
Treatment for Paget's Disease, Approved April 1998
Estratab (.3 mg ); Solvay Pharmaceuticals;
Treatment for the prevention of osteoporosis, Approved March 1998
Etodolac; Faulding;
Generic equivalent of Lodine 500 mg tablets, Approved May 1998
Lodine XL (etodolac); Wyeth;
Treatment for arthritis, Approved February 1998
Lovenox (enoxaparin sodium) Injection; Rhone Poulenc Rorer;
Treatment for prevention of blood clots following hip-replacement surgery, Approved February 1998
Drugs Approved in 1997
Arthrotec; Searle;
Treatment for arthritis, Approved December 1997
Atracurium Besylate Injection; Faulding;
Generic equivalent of Tracrium, Approved April 1997
Estradiol tablets; Barr Laboratories;
Generic equivalent of Estrace, Approved October 1997
Etodolac; Royce Laboratories;
Generic equivalent of Lodine, Approved December 1997
Evista (raloxifene hydrochloride); Eli Lilly;
Treatment for the prevention of osteoporosis, Approved December 1997
Ketoprofen; Schein Pharmaceutical;
Generic equivalent or Oruvail, Approved December 1997
Skelid (tiludronate disodium); Sanofi-aventis;
Treatment for Paget’s disease of bone, Approved March 1997
Synvisc, Synvisc-One (Hylan GF 20); Genzyme;
For the treatment of pain associated with osteoarthritis of the knee, Approved August 1997
Tolmetin Sodium; Teva Pharmaceutical;
Treatment for arthritis, Approved March 1997
Drugs Approved in 1996
Kadian; Purepac Pharmaceutical;
Treatment for chronic moderate to severe pain, Approved July 1996
Naprelan (naproxen sodium); Elan Pharmaceuticals, Wyeth;
Treatment for osteoarthritis and rheumatoid arthritis, Approved January 1996
OxyContin (oxycodone HCl controlled-release); Purdue Pharma;
Treatment for pain associated with musculoskeletal conditions, Approved May 1996
Saizen; Ares-Serono;
Treatment for growth hormone deficiency and Turner Syndrome, Approved May 1996
Seprafilm; Genzyme;
Treatment for the reduction of scar tissue as a result of abdominal or pelvic surgery, Approved August 1996
Zanaflex (tizanidine hydrochloride); Elan Pharmaceuticals;
Treatment for muscle spasticity, Approved December 1996
Drugs Approved in 1995
Fosamax (alendronate sodium); Merck;
Treatment for osteoporosis in women after menopause and Paget's Disease of Bone, Approved on September 29, 1995
Miacalcin (calcitonin-salmon) Nasal Spray; Sandoz Pharmaceuticals;
Treatment for post-menopausal osteoporosis, Approved on August 17, 1995
Prempro & Premphase (conjugated estrogens/medroxyprogesterone acetate tablets); Wyeth;
Treatment for postmenopausal hormone replacement, postmenopausal osteoporosis, Approved November 1995
